Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis.
about
Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectivesImatinib dose escalation versus sunitinib as a second-line treatment against advanced gastrointestinal stromal tumors: A nationwide population-based cohort study.Mesenteric fibromatosis after resection for gastrointestinal stromal tumor of stomach: A case report.Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
P2860
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 September 2015
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Imatinib dose escalation versu ...... IST: a retrospective analysis.
@en
Imatinib dose escalation versu ...... IST: a retrospective analysis.
@nl
type
label
Imatinib dose escalation versu ...... IST: a retrospective analysis.
@en
Imatinib dose escalation versu ...... IST: a retrospective analysis.
@nl
prefLabel
Imatinib dose escalation versu ...... IST: a retrospective analysis.
@en
Imatinib dose escalation versu ...... IST: a retrospective analysis.
@nl
P2093
P2860
P50
P356
P1433
P1476
Imatinib dose escalation versu ...... IST: a retrospective analysis.
@en
P2093
Antonio Russo
Bruno Vincenzi
Delia De Lisi
Giuseppe Badalamenti
Giuseppe Bronte
Giuseppe Tonini
Margherita Nannini
Maria Abbondanza Pantaleo
P2860
P304
69412-69419
P356
10.18632/ONCOTARGET.5136
P407
P50
P577
2015-09-24T00:00:00Z